Article Text

Download PDFPDF
Choriocapillaris impairment around the atrophic lesions in patients with geographic atrophy: a swept-source optical coherence tomography angiography study
  1. Marco Nassisi1,2,
  2. Yue Shi1,2,
  3. Wenying Fan1,2,3,
  4. Enrico Borrelli1,2,4,
  5. Akihito Uji1,2,
  6. Michael S Ip1,2,
  7. Srinivas R Sadda1,2
  1. 1 Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, USA
  2. 2 Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
  3. 3 Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Sciences Key Laboratory, Capital Medical University, Beijing, China
  4. 4 Ophthalmology Clinic, Department of Medicine and Science of Ageing, University G. D'Annunzio Chieti-Pescara, Chieti, Italy
  1. Correspondence to Dr Srinivas R Sadda, Doheny Eye Institute, Doheny Image Reading Center, Los Angeles, CA 90033, USA; ssadda{at}doheny.org

Footnotes

  • Contributors MN, MSI and SRS were involved in study design, collection and analysis of the data as well as drafting of the manuscript. YS, WF, EB and AU were involved in study design, data collection and critical review of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MSI: Thrombogenics (C), Omeros (C), Boehringer Ingelheim (C), Genentech (C), Quark (C), Astellas Institute for Regenerative Medicine (C), Allergan (C). SRS: Allergan (C,F), Carl Zeiss Meditec (F), CenterVue (C), Genentech (C,F), Heidelberg Engineering (C), Iconic (C), NightstarX (C), Novartis (C), Optos (C,F), Thrombogenics (C), Topcon (C).

  • Patient consent Obtained.

  • Ethics approval Institutional review board (IRB) of the University of California–Los Angeles (UCLA).

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors MN, MSI and SRS were involved in study design, collection and analysis of the data as well as drafting of the manuscript. YS, WF, EB and AU were involved in study design, data collection and critical review of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MSI: Thrombogenics (C), Omeros (C), Boehringer Ingelheim (C), Genentech (C), Quark (C), Astellas Institute for Regenerative Medicine (C), Allergan (C). SRS: Allergan (C,F), Carl Zeiss Meditec (F), CenterVue (C), Genentech (C,F), Heidelberg Engineering (C), Iconic (C), NightstarX (C), Novartis (C), Optos (C,F), Thrombogenics (C), Topcon (C).

  • Patient consent Obtained.

  • Ethics approval Institutional review board (IRB) of the University of California–Los Angeles (UCLA).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost B Jonas